Evidence map›Paper›PMID 37160530›Full record

ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2023

Nanoparticles Enhance Solubility and Neuroprotective Effects of Resveratrol in Demyelinating Disease.

Ehtesham Shamsher, Reas S Khan, Benjamin M Davis, Kimberly Dine, Vy Luong, Satyanarayana Somavarapu, M Francesca Cordeiro, Kenneth S Shindler

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Advances in Therapeutics Research for Demyelinating Diseases.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Ehtesham ShamsherInstitute of Ophthalmology, University College London, London, UK.
Reas S KhanDepartments of Ophthalmology and Neurology, Scheie Eye Institute, University of Pennsylvania, 51 N 39th Street, Philadelphia, PA, 19104, USA.
Benjamin M DavisInstitute of Ophthalmology, University College London, London, UK.
Kimberly DineDepartments of Ophthalmology and Neurology, Scheie Eye Institute, University of Pennsylvania, 51 N 39th Street, Philadelphia, PA, 19104, USA.
Vy LuongInstitute of Ophthalmology, University College London, London, UK.
Satyanarayana SomavarapuSchool of Pharmacy, University College London, London, UK.
M Francesca CordeiroInstitute of Ophthalmology, University College London, London, UK.
Kenneth S ShindlerDepartments of Ophthalmology and Neurology, Scheie Eye Institute, University of Pennsylvania, 51 N 39th Street, Philadelphia, PA, 19104, USA. kenneth.shindler@pennmedicine.upenn.edu.ORCID 0000-0003-2417-258X
Penn Presbyterian Medical Center · USUniversity College London · GBHôpital Ophtalmique Jules-Gonin · CHWestern Eye Hospital · GB

Funding

Mechanism of SIRT1 Activator Mediated Neuroprotection of Retinal Ganglion CellsR01EY019014 · NEI · UNIVERSITY OF PENNSYLVANIA · PI SHINDLER, KENNETH S · 2010 to 2020
$3.7M
NEI NIH HHS R01 EY019014
6 · The paper itself

Abstract

Resveratrol is a natural polyphenol which may be useful for treating neurodegenerative diseases such as multiple sclerosis (MS). To date, current immunomodulatory treatments for MS aim to reduce inflammation with limited effects on the neurodegenerative component of this disease. The purpose of the current study is to develop a novel nanoparticle formulation of resveratrol to increase its solubility, and to assess its ability to prevent optic nerve and spinal cord degeneration in an experimental autoimmune encephalomyelitis (EAE) mouse model of MS. Resveratrol nanoparticles (RNs) were made using a thin rehydration technique. EAE mice received a daily oral administration of vehicle, RNs or unconjugated resveratrol for one month. They were assessed daily for clinical signs of paralysis and weekly for their visual acuity with optokinetic responses (OKR). After one month, their spinal cords and optic nerves were stained for inflammation and demyelination and retinal ganglion cells immunostained for Brn3a. RNs were stable for three months. The administration of RNs did not have any effect on clinical manifestation of EAE and did not preserve OKR scores but reduced the intensity of the disease. It did not reduce inflammation and demyelination in the spinal cord and the optic nerve. However, RNs were able to decrease RGC loss compared to the vehicle. Results demonstrate that resveratrol is neuroprotective by reducing RGC loss. Interestingly, neuroprotective effects and decreased disease severity occurred without reduction of inflammation or demyelination, suggesting this therapy may fill an unmet need to limit the neurodegenerative component of MS.

Indexed as

Encephalomyelitis, Autoimmune, ExperimentalMultiple SclerosisNeuroprotective AgentsOptic NeuritisAnimalsDisease Models, AnimalInflammationMiceMice, Inbred C57BLResveratrolSolubilityNeuroprotective AgentsResveratrolMultiple sclerosisNeuroprotectionOptic neuritisResveratrol

Identifiers

PMID37160530
PMCPMC10457259
OpenAlexW4376121426

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.